The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials
Open accessAbstract
BACKGROUND: Mild cognitive impairment (MCI) refers to a transitional zone between normal ageing and dementia. Despite the uncertainty regarding the definition of MCI as a clinical entity, clinical trials have been conducted in the attempt to study the role of cholinesterase inhibitors (ChEIs) currently approved for symptomatic treatment of mild to moderate Alzheimer disease (AD), in preventing progression from MCI to AD. The objective of this review is to assess the effects of ChEIs (donepezil, rivastigmine, and galantamine) in delaying the conversion from MCI to Alzheimer disease or dementia. METHODS AND FINDINGS: The terms "donepezil", "rivastigmine", "galantamine", and "mild cognitive impairment" and their variants, synonyms, and acronyms were used as search terms in four electronic databases (MEDLINE, EMBASE, Cochrane, PsycINFO) and three registers: the Cochrane Collaboration Trial Register, Current Controlled Trials, and ClinicalTrials.gov. Published and unpublished studies were included if they were randomized clinical trials published (or described) in English and conducted among persons who had received a diagnosis of MCI and/or abnormal memory function documented by a neuropsychological assessment. A standardized data extraction form was used. The reporting quality was assessed using the Jadad scale. Three published and five unpublished trials met the inclusion criteria (three on donepezil, two on rivastigmine, and three on galantamine). Enrolment criteria differed among the trials, so the study populations were not homogeneous. The duration of the trials ranged from 24 wk to 3 y. No significant differences emerged in the probability of conversion from MCI to AD or dementia between the treated groups and the placebo groups. The rate of conversion ranged from 13% (over 2 y) to 25% (over 3 y) among treated patients, and from 18% (over 2 y) to 28% (over 3 y) among those in the placebo groups. Only for two studies was it possible to derive point estimates of the relative risk of conversion: 0.85 (95% confidence interval 0.64-1.12), and 0.84 (0.57-1.25). Statistically significant differences emerged for three secondary end points. However, when adjusting for multiple comparisons, only one difference remained significant (i.e., the rate of atrophy in the whole brain). CONCLUSIONS: The use of ChEIs in MCI was not associated with any delay in the onset of AD or dementia. Moreover, the safety profile showed that the risks associated with ChEIs are not negligible. The uncertainty regarding MCI as a clinical entity raises the question as to the scientific validity of these trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,332
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
What Makes Clinical Research Ethical?
Emanuel, E. J. (2000) · JAMA · doi:10.1001/jama.283.20.2701 · Cited by 2,710
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Mild Cognitive Impairment as a Clinical Entity and Treatment Target
Petersen, R. C., & Morris, J. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1160 · Cited by 935
Moynihan, R., G⊘tzsche, P. C., Heath, I., & Henry, D. (2002) · BMJ · doi:10.1136/bmj.324.7342.886 · Cited by 900
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Incidence and outcome of mild cognitive impairment in a population-based prospective cohort
Larrieu, S., Letenneur, L., Orgogozo, J. M., Fabrigoule, C., Amieva, H., Le Carret, N., Barberger–Gateau, P., & Dartigues, J. F. (2002) · Neurology · doi:10.1212/01.wnl.0000034176.07159.f8 · Cited by 668
Vascular risk factors, incidence of MCI, and rates of progression to dementia
Solfrizzi, V., Panza, F., Colacicco, A. M., D’Introno, A., Capurso, C., Torres, F., Grigoletto, F., Maggi, S., Del Parigi, A., Reiman, E. M., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000144281.38555.e3 · Cited by 530
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
National Estimates of the Quantity and Cost of Informal Caregiving for the Elderly with Dementia*
Langa, K. M., Chernew, M. E., Kabeto, M. U., Regula Herzog, A., Beth Ofstedal, M., Willis, R. J., Wallace, R. B., Mucha, L. M., Straus, W. L., & Fendrick, A. M. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.10123.x · Cited by 456
Mild cognitive impairment: conceptual basis and current nosological status
Ritchie, K., & Touchon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(99)06155-3 · Cited by 392
Galantamine for Alzheimer's disease and mild cognitive impairment
Loy, C., & Schneider, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001747.pub3 · Cited by 322
Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial
Salloway, S., Ferris, S., Kluger, A., Goldman, R., Griesing, T., Kumar, D., & Richardson, S. (2004) · Neurology · doi:10.1212/01.wnl.0000134664.80320.92 · Cited by 300
The Fight against Disease Mongering: Generating Knowledge for Action
Moynihan, R., & Henry, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030191 · Cited by 293
Alzheimer disease: progress or profit?
Mount, C., & Downton, C. (2006) · Nature Medicine · doi:10.1038/nm0706-780 · Cited by 262
DeCarli, C. (2007) · Archives of Neurology · doi:10.1001/archneur.64.1.108 · Cited by 212
Mild cognitive impairment clinical trials
Petersen, R. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1155 · Cited by 177
Risk factors for transitions from normal to mild cognitive impairment and dementia
Kryscio, R. J., Schmitt, F. A., Salazar, J. C., Mendiondo, M. S., & Markesbery, W. R. (2006) · Neurology · doi:10.1212/01.wnl.0000203264.71880.45 · Cited by 174
Donepezil for mild cognitive impairment
Birks, J., & Flicker, L. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006104 · Cited by 169
Clinical trials in mild cognitive impairment: lessons for the future
Jelic, V (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.072926 · Cited by 158
Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
Visser, P. J., Scheltens, P., & Verhey, F. R. J. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.047720 · Cited by 140
Mild Cognitive Impairment Is Not a Clinical Entity and Should Not Be Treated
Gauthier, S. G., & Touchon, J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1164 · Cited by 120
A Clinical Approach to Mild Cognitive Impairment
Rosenberg, P. B., Johnston, D. M., & Lyketsos, C. G. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1884 · Cited by 88
Galisteo, M., Rissel, M., Sergent, O., Chevanne, M., Cillard, J., Guillouzo, A., & Lagadic‐Gossmann, D. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39052-4 · Cited by 79
Koontz, J., & Baskys, A. (2005) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750502000502 · Cited by 62
Role of cholinesterase inhibitors in dementia care needs rethinking
Pelosi, A. J., McNulty, S. V., & Jackson, G. A. (2006) · BMJ · doi:10.1136/bmj.38945.478160.94 · Cited by 56
Alzheimer's Disease — Clinical Trials and the Logic of Clinical Purpose
Karlawish, J. H. (2006) · New England Journal of Medicine · doi:10.1056/nejme068163 · Cited by 17
Mild cognitive impairment: To treat or not to treat
Kirshner, H. S. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0033-0 · Cited by 14
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Review Article: Genetics of Alzheimer Disease
Bekris, L. M., Yu, C.-E., Bird, T. D., & Tsuang, D. W. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383571 · Cited by 1,029
Resistance Training and Executive Functions: A 12-Month Randomized Controlled Trial
Liu-Ambrose, T. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.494 · Cited by 775
Plassman, B. L., Williams, J. W., Burke, J. R., Holsinger, T., & Benjamin, S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-3-201008030-00258 · Cited by 681
Metadata
- Authors
- Raschetti, R., Albanese, E., Vanacore, N., & Maggini, M.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-11-27
- Volume
- 4
- Issue
- 11
- Pages
- e338
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2049890856
- Cited by
- 321
- References
- 32
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.